Scholarlink

Background <p>Proteinuria reduction is considered a potential surrogate endpoint predictive of reflecting long-term kidney prognosis in IgA nephropathy (IgAN), but quantitative evidence in Japanese patients is limited. We aimed to examine the association between short-term proteinuria reduction at 12&#xa0;months and long-term kidney outcomes in Japan IgA Nephropathy Cohort Study (J-IGACS).</p> Methods <p>Participants from J-IGACS were categorized into tertiles based on their 12-month proteinuria-to-baseline proteinuria ratios. The primary outcome was a composite of ≥ 40% estimated glomerular filtration rate (eGFR) decline or initiation of kidney-replacement therapy. Associations between proteinuria ratio and outcomes were assessed using Cox proportional hazards models and restricted cubic splines. Multivariable analyses adjusted for age, sex, baseline eGFR, log-transformed proteinuria, Oxford classification scores, and use of corticosteroids and renin–angiotensin–aldosterone system inhibitors within 12&#xa0;months.</p> Results <p>Among 792 patients, those in the greatest proteinuria reduction had significantly lower risk of the primary endpoint (<i>P</i> for trend &lt; 0.001) and a more favorable eGFR slope. Spline analysis showed a continuous, dose–response association between proteinuria ratio and improved outcomes. These findings remained robust in sensitivity analyses restricted to patients likely qualifying for clinical trials. The results showed that patients with lower proteinuria ratios tended to have slower rates of eGFR decline (<i>P</i> for trend &lt; 0.001).</p> Conclusion <p>Proteinuria reduction within the first-year post-diagnosis is independently associated with lower risk of adverse kidney outcomes and a slower decline in kidney function in patients with IgAN. These results support the use of proteinuria reduction as a surrogate endpoint in both clinical trials and disease management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Initial proteinuria reduction and adverse kidney outcomes in IgA nephropathy: an analysis from the J-IGACS

  • 期刊论文

  • 发表日期：

    2025年12月20日

查看全文
  • Takaya Sasaki,
  • Nobuo Tsuboi,
  • Kentaro Koike,
  • Hiroyuki Ueda,
  • Masahiro Okabe,
  • Shinya Yokote,
  • Akihiro Shimizu,
  • Keita Hirano,
  • Tetsuya Kawamura,
  • Takashi Yokoo,
  • Yusuke Suzuki

摘要

Background

Proteinuria reduction is considered a potential surrogate endpoint predictive of reflecting long-term kidney prognosis in IgA nephropathy (IgAN), but quantitative evidence in Japanese patients is limited. We aimed to examine the association between short-term proteinuria reduction at 12 months and long-term kidney outcomes in Japan IgA Nephropathy Cohort Study (J-IGACS).

Methods

Participants from J-IGACS were categorized into tertiles based on their 12-month proteinuria-to-baseline proteinuria ratios. The primary outcome was a composite of ≥ 40% estimated glomerular filtration rate (eGFR) decline or initiation of kidney-replacement therapy. Associations between proteinuria ratio and outcomes were assessed using Cox proportional hazards models and restricted cubic splines. Multivariable analyses adjusted for age, sex, baseline eGFR, log-transformed proteinuria, Oxford classification scores, and use of corticosteroids and renin–angiotensin–aldosterone system inhibitors within 12 months.

Results

Among 792 patients, those in the greatest proteinuria reduction had significantly lower risk of the primary endpoint (P for trend < 0.001) and a more favorable eGFR slope. Spline analysis showed a continuous, dose–response association between proteinuria ratio and improved outcomes. These findings remained robust in sensitivity analyses restricted to patients likely qualifying for clinical trials. The results showed that patients with lower proteinuria ratios tended to have slower rates of eGFR decline (P for trend < 0.001).

Conclusion

Proteinuria reduction within the first-year post-diagnosis is independently associated with lower risk of adverse kidney outcomes and a slower decline in kidney function in patients with IgAN. These results support the use of proteinuria reduction as a surrogate endpoint in both clinical trials and disease management.